Study: Alzheimer's drug shows modest success slowing declines in memory, thinking
In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.
An experimental drug that removes a substance called amyloid from the brain appears to slow down Alzheimer's disease.
The drug, called lecanemab, reduced the rate of cognitive decline by 27% in a study of nearly 1,800 people in the early stages of Alzheimer's, scientists reported at the meeting in San Francisco.
